PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/16

A1

(11) International Publication Number: WO 99/59550

(43) International Publication Date: 25 November 1999 (25.11.99)

(21) International Application Number: PCT/US99/10975

(22) International Filing Date: 19 May 1999 (19.05.99)

(30) Priority Data:
60/086,108 20 May 1998 (20.05.98) US

(71) Applicant: THE LIPOSOME COMPANY, INC. [US/US]; One Research Way, Princeton Forrestal Center, Princeton, NJ 08540 (US).

(72) Inventors: PERKINS, Walter; 248 Federal City Road, Trenton, NJ 08638 (US). LI, Xingong; 130 Tullytown Road, Levittown, PA 19054 (US). HIRSCH, Donald; 6 Avalon Road, Trenton, NJ 08638 (US). MAYHEW, Eric; 26 Allison Court, Monmouth Junction, NJ 08852 (US). AHMAD, Imran; 12 Pinehurst, Cranbury, NJ 08512 (US). ALI, Shaukat; 24 Jamie Court, Monmouth Junction, NJ 08852 (US). JANOFF, Andrew; 560 Countess Drive, Yardley, PA 19067 (US).

(74) Agent: GOODMAN, Rosanne; The Liposome Company, Inc., One Research Way, Princeton Forrestal Center, Princeton, NJ 08540 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NOVEL PARTICULATE FORMULATIONS

(57) Abstract

This invention provides vehicles capable of delivering high concentrations of poorly hydrophilic/poorly lipophilic compounds to animals, by combining compounds having biocompatible hydrophobic domains with conjugates having both hydrophobic and hydrophilic regions. Such formulations are suitable for a number of uses in animals, particularly the administration thereto of high concentrations of therapeutically useful compound, without an undue level of side effects.